Sadettin Uslu

Celal Bayar University Faculty of Medicine #Rheumatology and Internal Medicine / Rheumatologist / Assoc. Prof. Dr.

[Sadettin Uslu @sadouslu]

🆕‘‘Assessing safety and efficacy of TNFi treatment in late onset #ankylosingspondylitis : a TURKBIO registry study’’⁦ @SciReports⁩ 👇 https://t.co/puL8KQaLfO

[Nelly ZIADE 🍀 @Nellziade]

Many drugs in the pipeline for #Systemic_Sclerosis

In particular, stay tuned for:
🔺Nerandomilast (PDE4i) in ILD
🔺CAR T cells (obviously): big RCT trials planned
🔺Bispecific T cell engagers: Teclistamab

#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow

[Janet Pope @Janetbirdope]

Controversial

#Rheumatoid #arthritis disease activity
May not affect #ILD
BUT affects #mortality
level evidence +/-
PHillippe Dieude said

#Rx from RCTs
#IS
Ex #rituximab

#antifibrotics
#nintedanib
#nerandomilast

HOw to Treat RA-ILD June 5
#EULAR2026 @RheumNow @eular_ARD

[Roxana González @RoxOsler]

IL-6 blockade has transformed the treatment of GCA. But is targeting a single cytokine enough? Persistent T-cell infiltrates within the vessel wall, relapses after tocilizumab withdrawal and the role of IFNγ suggest a more complex disease biology. #EULAR2026

[Burhan Fatih Koçyiğit @BurhanFatihKoy1]

Retraction Analysis in Social Media Research: A Scopus Based Data From 2011 to 2025
👇👇👇
https://t.co/AQ0UsDsi8a
@sadouslu
@NeslihanGken7
@anarsiknotrofil @ahmetusen @OlenaZimba @ArmenYuri

[Neslihan Gokcen @NeslihanGken7]

My sincere thanks to the organizing committee of the “3rd Manisa Rheumatology Days” for the thoughtfully prepared program and excellent organization. It was a pleasure to be part of such a valuable and inspiring meeting 🙏🏼🌿 @sadouslu @OzgurAkgulMD @Nurullah_Akkoc

[Burhan Fatih Koçyiğit @BurhanFatihKoy1]

It was a beneficial presentation with a great mentor! Peer-review in scientific publishing system. @OlenaZimba @ArmenYuri @NeslihanGken7 @sadouslu

[Armen Yuri Gasparyan @ArmenYuri]

Peer review guidance: a primer for researchers
@OlenaZimba @BurhanFatihKoy1 @anarsiknotrofil @dr_emrebilgin @sadouslu @NeslihanGken7 @hande_snc @abdulvahap_md @ozlemkilic_md @GencTRASD
https://t.co/vvKtUF4fVY

[Armen Yuri Gasparyan @ArmenYuri]

The effect of tumor necrosis factor-alpha on rheumatoid arthritis-related pain: overview of evidence and mechanistic pathways
@BurhanFatihKoy1 @NeslihanGken7 @dr_emrebilgin @sadouslu @anarsiknotrofil @abdulvahap_md @Gulsandaluzun @ozlemkilic_md
https://t.co/vmFnkQyNnZ

[NEJM @NEJM]

Inflammatory myopathies are typically associated with a myositis-specific autoantibody that determines the diagnosis and prognosis. Myositis subgroups have distinct pathomechanisms that now allow for targeted therapies.

Learn more in the Review Article “Inflammatory Myopathies” by Yves Allenbach, MD, PhD, and Olivier Benveniste, MD, PhD: https://t.co/ZeCKdNe87v

[Armen Yuri Gasparyan @ArmenYuri]

MANUSCRIPTS WITH FAKE CHATGPT-CREATED REFERENCES: A CASE STUDY | Cent Asian J Med Hypotheses Ethics
@dr_emrebilgin @NeslihanGken7 @sadouslu @abdulvahap_md @DDoskaliuk @Birzhan7101423 @ZaferKocak14 @KasapcopurOzgur @Tati03153937 @KardumZeljka
https://t.co/V0LB8Z7Gxx

[Armen Yuri Gasparyan @ArmenYuri]

Medical Photography for Scientific Publishing (MedPhotoPubl) in Rheumatology and Rehabilitation
@BurhanFatihKoy1 @dr_emrebilgin @sadouslu @NeslihanGken7 @dr_ismihan @abdulvahap_md
https://t.co/huodRdnk2G

[Burhan Fatih Koçyiğit @BurhanFatihKoy1]

The effect of structured hand massage on hand function and grip strength in rheumatoid arthritis patients: a randomized controlled pilot study
👇👇👇
https://t.co/htxDMGmZZh
@anarsiknotrofil
@kcygte @NeslihanGken7 @sadouslu
@ahmetak20160685 @ahmetusen @OlenaZimba @ArmenYuri

[Burhan Fatih Koçyiğit @BurhanFatihKoy1]

Systemic lupus erythematosus-related infections in pregnancy: a cross-sectional bibliometric analysis
👇👇👇
https://t.co/zkDpmjH81O
@abdulvahap_md @sadouslu @ahmetusen @ahmetak20160685 @anarsiknotrofil @OlenaZimba @ArmenYuri @Rheumatol_Int

[NatRevRheumatol @NatRevRheumatol]

New content online: Advances in the pathophysiology, diagnosis and treatment of Takayasu arteritis https://t.co/brxYbSD8Ix

[Mithu Maheswaranathan, MD @MithuRheum]

🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋

Just Released: Nov 3 #ACR25 🔥
🔸Review organ-specific treatment recommendations
🔸Steroid & HCQ Use Guidance

➠ Read the Full Guideline: https://t.co/jNwvKWbFpE

#RheumX #RheumTwitter #Rheum @RheumNow

[JCR: Journal of Clinical Rheumatology @JRheumatology]

🫁 SSc-ILD therapy — expert survey
• MMF first-line (92%)
• Escalation: RTX or TCZ
• 57% add nintedanib; 24% combo IS (often MMF+RTX)
• Prednisone used more than expected
See details 🔗 #SScILD #RheumTwitter
https://t.co/LSx17ahsYb

[Dr.Mukesh , MD , DM @dr_immuno29]

🧵 #ACR25 Highlights – SARD-ILD (Part 1)

Erin Wilfong MD PhD (Vanderbilt University)

🫁 Personalized care for CTD-ILD: The era of precision rheumatology

🔹 Guideline Pulse:
→ Mycophenolate = cornerstone across SARD-ILDs.
→ Rituximab, Tocilizumab, Nintedanib gaining momentum.
→ 🚫 Long-term steroids discouraged.

🔹 RA-ILD:
→ 10 % precede arthritis onset.
→ MTX safe — may delay ILD onset.
→ TNFi ok; RTX favoured if progressive.
→ Treat-to-target (CDAI/DAS28) + add anti-fibrotic if needed.

🔹 Systemic Sclerosis-ILD:
→ MMF ≈ CYC (SLS-II) but better tolerated.
→ Tocilizumab preserves FVC.
→ RTX stabilizes FVC + mRSS.
→ MMF + Nintedanib = synergy for progressive disease.

💡 Integrate clinical activity + fibrosis pattern + autoantibody profile for precision therapy.

#ACR25 #ILD #SARD #ConnectiveTissueDisease #RheumTwitter #ACRAmbassador

[Richard Conway @RichardPAConway]

NEREA registry study on mortality in progressive pulmonary fibrosis in SARD-ILD. 158 patients. Median survival 7.8 years. DMARD use associated improved mortality. @RheumNow #ACR25 Abstr#1024

[Rheuma Doc @LastManStand85]

The Validated Screening Algorithms for Systemic Sclerosis related Pulmonary Hypertension #Rheumatology #MedTwitter #ACR2025

[Roxana González @RoxOsler]

#ReviewCourse #ACR25 vasculitides & CNS involvement
🔹 Takayasu,PAN & ANCA-associated: CNS dysfunction rare but life-threatening.
🔹 GCA/PMR:overlapping inflammatory spectrum.
🔹 Behçet’s: parenchymal vs. cerebral venous thrombosis forms.
💊 Therapy: cyclophosphamide or TNF/IL-6